By Fineline Cube Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license agreement with Genentech, a member of the Roche Group (SWX: ROP; OTCMKTS: RHHBY), to develop next-generation antibody-drug conjugates (ADCs) based on Duality Biologics’ proprietary DualityBio Unique Payload Antibody Conjugate Platform (DUPAC). The deal, featuring a USD 45m upfront payment and over USD 1b in potential milestones, marks another major validation of Chinese ADC platform technology by a top-tier global pharma player.
Deal Overview
| Element | Detail |
|---|---|
| Parties | Duality Biologics (HKG: 9606) and Genentech (Roche Group) |
| Agreement Type | Global collaboration and license agreement |
| Scope | Next-generation ADCs based on the DUPAC platform against tumor targets designated by Genentech |
| Upfront Payment | USD 45m |
| Potential Milestones | Over USD 1b across development, regulatory, and commercial milestones (all programs) |
| Royalties | Tiered royalties based on annual net sales of approved products |
| Date | 28 Aug 2026 |
Platform & Responsibilities
- Technology: The DUPAC (DualityBio Unique Payload Antibody Conjugate) platform, Duality Biologics’ proprietary novel payload antibody conjugate platform
- Duality Biologics’ Role: Utilize DUPAC payloads to generate and develop ADCs against Genentech-designated tumor targets; lead drug discovery and global early-stage clinical development
- Genentech’s Role: Obtain exclusive global licenses to the collaboration ADCs; independently assume responsibility for subsequent clinical development and commercialization following completion of Phase Ia
Division of Labor by Development Stage
| Stage | Lead Party |
|---|---|
| Drug discovery & ADC generation | Duality Biologics |
| Global early-stage clinical development (through Phase Ia) | Duality Biologics |
| Late-stage clinical development (post-Phase Ia) | Genentech |
| Commercialization | Genentech |
Under the structure, Duality Biologics retains control through the earliest clinical proof point, after which Genentech — one of the world’s leading oncology companies — takes over full development and commercialization. This handoff model lets the biotech focus capital on discovery and early clinical execution while leveraging Genentech’s global late-stage machinery.
Market Impact & Outlook
- Platform Validation: A collaboration with Genentech built on the DUPAC platform — not a single asset — signals confidence in Duality Biologics’ next-generation payload technology as a durable engine for ADC innovation
- Economics: The USD 45m upfront, USD 1b+ milestone stack, and tiered royalties provide a multi-year, diversified revenue profile without diluting equity
- ADC Sector Momentum: The deal extends the wave of global pharma licensing China-originated ADC science, reinforcing the country’s position as a hotbed of conjugate technology
- Strategic Optionality: With Genentech financing late-stage development and commercialization, Duality Biologics (HKG: 9606) preserves resources to expand its own pipeline and pursue additional platform partnerships
Forward‑Looking Statements – This brief contains forward-looking statements regarding collaboration outcomes, milestone achievement, and product commercialization. Milestone payments are contingent on future events and may not be realized. Not investment advice.-Fineline Info & Tech